Decreased function of fatty acid desaturase 1 is associated with placental foetal vascular malperfusion and highlights the key role of the maternal–foetal interface
BACKGROUND: Placental foetal vascular malperfusion (PFVM) is a chronic disorder characterised by impaired blood flow and abnormal vascular development, inducing adverse neonatal outcomes. Long chain polyunsaturated fatty acids (LC-PUFAs) play a crucial role in placenta health. We aimed to explore the role of genetic variation in LC-PUFA metabolism in PFVM risk as well as underlying mechanisms. METHODS: Associations were examined between two functional polymorphisms (rs174538 and rs174556) of the fatty acid desaturase 1 (FADS1) gene encoding the rate-limiting enzyme for LC-PUFA metabolism and PFVM among pregnant women (n = 646). Placental transcriptomes were correlated with PFVM and FADS1 genotypes. Various assays were performed in human umbilical vein endothelial cells and trophoblasts with FADS1 inhibitor and LC-PUFA interventions to characterise their function changes. FINDINGS: Low-function alleles of both polymorphisms were significantly associated with increased PFVM risk and decreased placental FADS1 transcription level. In placenta tissue, lower FADS1 expression is also associated with PFVM. PFVM-associated genes are enriched to pathways related to immune responses, apoptosis, and angiogenesis, which overlap with the genes and pathways associated with the risk alleles and demonstrate a cell-type enrichment to endothelial cells. In vitro, FADS1 inhibition impairs multiple functions of and interactions between endothelial and trophoblast cells. These impairments are reversed by LC-PUFA supplementation. INTERPRETATION: These findings highlight the impact of maternal LC-PUFA homoeostasis in placenta health and suggest that maternal FADS1 variants can potentially be an early diagnostic marker for PFVM. Our data supports PUFA metabolism as a precision therapeutic or preventive target to reduce placental dysfunction risk. FUNDING: NIH, Wayne State University and Michigan State University.
Authors
- Zheyun Peng (ORCID: https://orcid.org/0000-0002-6417-8778)
- Carolyn M. Salafia (ORCID: https://orcid.org/0000-0003-4017-960X)
- Stephanie Nartey
- Jean M. Kerver (ORCID: https://orcid.org/0000-0001-5006-3622)
- Raina Nakova Fichorova (ORCID: https://orcid.org/0000-0002-9980-5735)
- Wanqing Liu (ORCID: https://orcid.org/0000-0001-7727-6900)
- Shahrazad T. Saab (ORCID: https://orcid.org/0000-0002-2093-5511)
- Ty Partridge (ORCID: https://orcid.org/0000-0002-2905-4737)
- Zhenjie Liu (ORCID: https://orcid.org/0000-0002-0878-4052)
- Nigel Paneth (ORCID: https://orcid.org/0000-0002-0151-966X)
- Tao Li (ORCID: https://orcid.org/0000-0003-1531-358X)
- Ze Long
- Tengfei Ma
- Douglas Ruden
- Yang Jiang
Institutions
- Eugene Applebaum College of Pharmacy and Health Sciences (US)
- Brigham and Women's Hospital (US)
- Central South University (CN)
- Henry Ford Health System (US)
- Wayne State University (US)
- Ball State University (US)
- University Hospitals of Cleveland (US)
- New York State Office for People With Developmental Disabilities (US)
- The Barbara Ann Karmanos Cancer Institute (US)
- Great Lakes Environmental Center (US)
- University Hospitals Cleveland Medical Center (US)
- Second Xiangya Hospital of Central South University (CN)
- Northwestern Michigan College (US)
- Case Western Reserve University (US)
- Michigan State University (US)
Publication Details
- Journal
- EBioMedicine
- Published
- 2026-10-17
- DOI
- https://doi.org/10.1016/j.ebiom.2026.106517
- Primary Topic
- Pregnancy and preeclampsia studies
- Type
- article
- Field-Weighted Citation Impact
- 0.00
Funders
- Wayne State University
- Michigan State University
- National Institutes of Health